SG11202101730SA - The use of alpha-2-adrenergic receptor agonists for improving vision - Google Patents
The use of alpha-2-adrenergic receptor agonists for improving visionInfo
- Publication number
- SG11202101730SA SG11202101730SA SG11202101730SA SG11202101730SA SG11202101730SA SG 11202101730S A SG11202101730S A SG 11202101730SA SG 11202101730S A SG11202101730S A SG 11202101730SA SG 11202101730S A SG11202101730S A SG 11202101730SA SG 11202101730S A SG11202101730S A SG 11202101730SA
- Authority
- SG
- Singapore
- Prior art keywords
- alpha
- receptor agonists
- adrenergic receptor
- improving vision
- vision
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720671P | 2018-08-21 | 2018-08-21 | |
| PCT/US2019/047305 WO2020041340A1 (en) | 2018-08-21 | 2019-08-20 | The use of alpha-2-adrenergic receptor agonists for improving vision |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202101730SA true SG11202101730SA (en) | 2021-03-30 |
Family
ID=67841225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202101730SA SG11202101730SA (en) | 2018-08-21 | 2019-08-20 | The use of alpha-2-adrenergic receptor agonists for improving vision |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20210205273A1 (en) |
| EP (1) | EP3840750A1 (en) |
| JP (1) | JP2021534217A (en) |
| KR (1) | KR20210047323A (en) |
| CN (1) | CN112823003A (en) |
| AR (1) | AR115991A1 (en) |
| AU (1) | AU2019325486A1 (en) |
| BR (1) | BR112021003295A2 (en) |
| CA (1) | CA3110318A1 (en) |
| CL (1) | CL2021000440A1 (en) |
| CO (1) | CO2021003460A2 (en) |
| IL (1) | IL280990A (en) |
| MX (1) | MX2021002112A (en) |
| PH (1) | PH12021550372A1 (en) |
| SG (1) | SG11202101730SA (en) |
| TW (1) | TW202021584A (en) |
| WO (1) | WO2020041340A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021168349A1 (en) * | 2020-02-20 | 2021-08-26 | Allergan, Inc. | Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| EP2525776B1 (en) | 2010-01-22 | 2015-10-28 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
| US10507245B2 (en) * | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| TWI631961B (en) | 2013-03-15 | 2018-08-11 | 美商歐樂根公司 | Prostamide-containing intraocular implant |
| CA2907881A1 (en) | 2013-03-27 | 2014-10-02 | Forsight Vision5, Inc. | Bimatoprost ocular silicone inserts and methods of use thereof |
| WO2014165308A2 (en) | 2013-04-01 | 2014-10-09 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
| US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
| US11077053B2 (en) * | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
-
2019
- 2019-08-20 US US17/055,922 patent/US20210205273A1/en not_active Abandoned
- 2019-08-20 BR BR112021003295-9A patent/BR112021003295A2/en unknown
- 2019-08-20 KR KR1020217008132A patent/KR20210047323A/en unknown
- 2019-08-20 TW TW108129699A patent/TW202021584A/en unknown
- 2019-08-20 JP JP2021510070A patent/JP2021534217A/en active Pending
- 2019-08-20 SG SG11202101730SA patent/SG11202101730SA/en unknown
- 2019-08-20 CN CN201980065608.3A patent/CN112823003A/en active Pending
- 2019-08-20 AU AU2019325486A patent/AU2019325486A1/en active Pending
- 2019-08-20 WO PCT/US2019/047305 patent/WO2020041340A1/en active Application Filing
- 2019-08-20 CA CA3110318A patent/CA3110318A1/en active Pending
- 2019-08-20 MX MX2021002112A patent/MX2021002112A/en unknown
- 2019-08-20 EP EP19762588.2A patent/EP3840750A1/en active Pending
- 2019-08-21 AR ARP190102374A patent/AR115991A1/en unknown
-
2021
- 2021-02-21 IL IL280990A patent/IL280990A/en unknown
- 2021-02-22 CL CL2021000440A patent/CL2021000440A1/en unknown
- 2021-02-22 PH PH12021550372A patent/PH12021550372A1/en unknown
- 2021-03-17 CO CONC2021/0003460A patent/CO2021003460A2/en unknown
- 2021-06-30 US US17/364,470 patent/US20220160623A1/en not_active Abandoned
- 2021-10-29 US US17/452,963 patent/US20220288031A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021550372A1 (en) | 2021-11-29 |
| BR112021003295A2 (en) | 2021-05-18 |
| US20220160623A1 (en) | 2022-05-26 |
| EP3840750A1 (en) | 2021-06-30 |
| CN112823003A (en) | 2021-05-18 |
| IL280990A (en) | 2021-04-29 |
| AR115991A1 (en) | 2021-03-17 |
| US20210205273A1 (en) | 2021-07-08 |
| CL2021000440A1 (en) | 2021-09-20 |
| JP2021534217A (en) | 2021-12-09 |
| US20220288031A1 (en) | 2022-09-15 |
| CA3110318A1 (en) | 2020-02-27 |
| CO2021003460A2 (en) | 2021-04-08 |
| TW202021584A (en) | 2020-06-16 |
| MX2021002112A (en) | 2021-07-16 |
| KR20210047323A (en) | 2021-04-29 |
| AU2019325486A1 (en) | 2021-03-25 |
| WO2020041340A1 (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3852735A4 (en) | Farnesoid x receptor agonists for the treatment of disease | |
| IL279300A (en) | Glp-1 receptor agonists and uses thereof | |
| IL279224A (en) | Glp-1 receptor agonists and uses thereof | |
| IL280290A (en) | Il2 agonists | |
| DK3762380T3 (en) | PHENYLPYRROLIDINONE FORMYLPEPTIDE-2 RECEPTOR AGONISTS | |
| IL276918A (en) | Ophthalmic formulation | |
| EP3810614C0 (en) | Bridged compounds as agonists of the muscarinic m1 and/or m4 receptor | |
| EP3440051A4 (en) | Neuropeptide s receptor (npsr) agonists | |
| IL292601A (en) | Npy2 receptor agonists | |
| EP3738501A4 (en) | Fundus imaging device | |
| IL280990A (en) | The use of alpha-2-adrenergic receptor agonists for improving vision | |
| PL3804653T3 (en) | Ocular goniometer | |
| IL268008A (en) | Ppargamma agonist for the treatment of huntington's disease | |
| ZAA201801093S (en) | Monitor console | |
| IL290024A (en) | Bicyclic cx3cr1 receptor agonists | |
| GB201903900D0 (en) | Adenosine receptor agonists | |
| IL277243A (en) | Substituted pyrazoles ffa4/gpr120 receptor agonists | |
| GB201820021D0 (en) | Ocular hydrogel compositions | |
| PL3773501T3 (en) | Intravaginal formulation | |
| GB201817943D0 (en) | Galanin-2 receptor agonists | |
| GB201805675D0 (en) | Compounds For Use As Apelin Receptor Antagonists | |
| GB201816747D0 (en) | Linear apelin receptor agonists | |
| GB201903985D0 (en) | GLP receptor agonists | |
| GB201914767D0 (en) | Linear apelin receptor agonists | |
| PL3508211T3 (en) | Composition for eye health |